Multiple myeloma (MM) wasn't exactly a headliner at last week's European Society for Medical Oncology (ESMO) 2018 Congress, and maybe that was fortuitous for the space. For the most part, ESMO presentations didn't set the biopharma world on fire. Instead, a number of companies – Adaptimmune Therapeutics plc, Aduro Biotech Inc., Biolinerx Ltd., Clovis Oncology Inc., Deciphera Pharmaceuticals Inc., Idera Pharmaceuticals Inc. and Merck & Co. Inc., among them – were singed by investors on unexciting data, sometimes from others simply in the same class.